Literature DB >> 25349054

Alendronate-induced unmasking or deterioration of coeliac disease: a case series.

B G A Stuckey1, R Sallie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25349054     DOI： 10.1007/s00198-014-2942-8

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  18 in total

1.  Increased small intestinal apoptosis in coeliac disease.

Authors:  S F Moss; L Attia; J V Scholes; J R Walters; P R Holt
Journal:  Gut       Date:  1996-12       Impact factor: 23.059

2.  Alendronate, a bisphosphonate, increased upper and lower gastrointestinal bleeding: risk factor analysis from a nationwide population-based study.

Authors:  Y-L Peng; H-Y Hu; J-C Luo; M-C Hou; H-C Lin; F-Y Lee
Journal:  Osteoporos Int       Date:  2014-02-25       Impact factor: 4.507

3.  Screening for antibodies against gliadin in patients with osteoporosis.

Authors:  E Lindh; S Ljunghall; K Larsson; B Lavö
Journal:  J Intern Med       Date:  1992-04       Impact factor: 8.989

Review 4.  Clinical features of celiac disease today.

Authors:  P Collin; K Kaukinen; M Mäki
Journal:  Dig Dis       Date:  1999       Impact factor: 2.404

5.  Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial.

Authors:  D C Bauer; D Black; K Ensrud; D Thompson; M Hochberg; M Nevitt; T Musliner; D Freedholm
Journal:  Arch Intern Med       Date:  2000-02-28

6.  Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Authors:  U A Liberman; S R Weiss; J Bröll; H W Minne; H Quan; N H Bell; J Rodriguez-Portales; R W Downs; J Dequeker; M Favus
Journal:  N Engl J Med       Date:  1995-11-30       Impact factor: 91.245

7.  Persistent mucosal damage and risk of fracture in celiac disease.

Authors:  Benjamin Lebwohl; Karl Michaëlsson; Peter H R Green; Jonas F Ludvigsson
Journal:  J Clin Endocrinol Metab       Date:  2014-01-16       Impact factor: 5.958

8.  Hypocalcemia after alendronate therapy in a patient with celiac disease.

Authors:  Shon E Meek; Kenneth Nix
Journal:  Endocr Pract       Date:  2007 Jul-Aug       Impact factor: 3.443

Review 9.  Esophagitis associated with the use of alendronate.

Authors:  P C de Groen; D F Lubbe; L J Hirsch; A Daifotis; W Stephenson; D Freedholm; S Pryor-Tillotson; M J Seleznick; H Pinkas; K K Wang
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

10.  Endoscopic comparison of alendronate alone and the enteric-coated alendronate with calcitriol combination in postmenopausal Korean females.

Authors:  Ji Oh Mok; Chan Hee Jung; Chul Hee Kim; Chang Beom Ryu; Yeo Joo Kim; Sang Jin Kim; Hyeong Kyu Park; Kyo Il Suh; Myung Hi Yoo; Dong-Won Byun
Journal:  Korean J Intern Med       Date:  2013-10-29       Impact factor: 2.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.